Attendees are taking a commemorative photo as Hwasun Chonnam National University Hospital and Hanmi Pharmaceutical signed a business agreement on the 15th to advance the utilization of medical big data. Provided by Hwasun Chonnam National University Hospital
Hwasun Chonnam National University Hospital (Director Min Jungjun) is accelerating its efforts to become a hub for cancer treatment and research in Asia by launching full-scale joint research and new drug development collaboration using medical big data with Hanmi Pharmaceutical Co., Ltd.
On the 16th, Hwasun Chonnam National University Hospital announced that it had signed a business agreement with Hanmi Pharmaceutical Co., Ltd. Through this agreement, the two organizations will establish a close partnership focused on several key areas: conducting goal-oriented joint research to meet medical needs at the clinical site; strengthening cooperation in new drug research and development through open innovation; jointly utilizing existing facilities, human resources, and collaborative networks; and carrying out big data-based cohort studies together.
After the agreement was signed, a project briefing session was held under the theme "Introduction to Health Insurance Big Data and Research Process Guidance." Kim Haseong, Head of the Data Strategy Group at Hanmi Pharmaceutical, introduced ways to utilize health insurance data and the research procedures to the attending researchers.
This session attracted significant interest from medical staff and researchers on site, providing an opportunity to enhance their practical understanding of big data-based research.
As a cancer-specialized hospital, Hwasun Chonnam National University Hospital has established a leading position in cancer treatment, biomedical research, medical big data, and advanced clinical trials. The hospital expects that this agreement will serve as a turning point to further strengthen its research competitiveness by forming a strategic collaboration with Hanmi Pharmaceutical, which possesses global new drug development capabilities based on world-class research infrastructure.
Director Min Jungjun stated, "This agreement will serve as an important milestone in organically connecting our vast clinical data and on-site capabilities with the industry as a research-oriented hospital. We will build an integrated ecosystem for precision medicine, medical AI, and clinical research to become the central hospital for cancer treatment in Asia."
Park Myeonghee, Head of Domestic Business Division at Hanmi Pharmaceutical, emphasized, "Research and development that combines precision medicine and big data is the core of future pharmaceuticals. By maximizing synergy with the medical capabilities of Hwasun Chonnam National University Hospital, we will contribute to the development of innovative new drugs."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
